Azitra Reports Zero Revenue and Increased Losses in Q2 and First Half of 2025

Azitra, Inc. reported its financial results for the second quarter and first half of 2025, revealing a continued lack of revenue and significant operational losses. For the three months ended June 30, 2025, the company recorded no service revenue, a decrease from $7,500 in the same period last year. The total operating expenses for the quarter amounted to $2.87 million, an increase of 8% compared to $2.67 million in the prior year. The net loss attributable to common shareholders for the quarter was $2.89 million, reflecting a 10% increase from the $2.63 million loss reported in the second quarter of 2024.

In the first half of 2025, Azitra's total revenue remained at zero, down from $7,500 in the first half of 2024. Operating expenses for this period rose to $5.97 million, up 6% from $5.63 million in the previous year. The net loss for the first six months was $5.96 million, a 7% increase from the $5.56 million loss reported in the same period last year. The increase in operating expenses was primarily driven by higher general and administrative costs, which rose by 9% to $3.32 million, and a 2% increase in research and development expenses to $2.65 million.

The company’s balance sheet as of June 30, 2025, showed total assets of approximately $4.0 million, a significant decrease from $7.36 million at the end of 2024. Cash and cash equivalents were reported at $1.05 million, down from $4.55 million at the end of the previous fiscal year. Azitra's accumulated deficit increased to $63.5 million, raising concerns about its ability to continue as a going concern. The company indicated that it would require substantial additional funding to support ongoing operations and product development.

Strategically, Azitra has been focused on advancing its clinical programs, particularly its lead candidates ATR-12 and ATR-04, which are in various stages of clinical trials. The company has also entered into an Equity Line of Credit with Alumni Capital, allowing it to raise up to $20 million through the sale of common stock. As of August 11, 2025, Azitra had issued 8,497,000 shares under this agreement, generating approximately $1.7 million in gross proceeds. The company is actively seeking additional financing options to support its operations and product development initiatives.

Looking ahead, Azitra anticipates a significant increase in research and development expenses as it progresses its clinical trials. However, the company faces substantial uncertainty regarding its ability to secure the necessary funding to continue its operations and achieve its strategic objectives. The management has expressed concerns about the company's financial viability, emphasizing the need for additional capital to support its ongoing research and development efforts.